Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. (Q38669331)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 July 2017

Language	Label	Description	Also known as
English	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.	scientific article published on 17 July 2017

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

0 references

1 reference

based on heuristic

inferred from title

Georgina V. Long

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Alexander M Menzies

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Richard F. Kefford

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Benjamin Y Kong

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

8

object named as

Antoni Ribas

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

12

object named as

F Stephen Hodi

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

John F Thompson

10

object named as

John A Thompson

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Alexander D Guminski

14

object named as

Alexander D Guminski

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

24

object named as

Matteo S Carlino

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Caroline E McNeil

6

object named as

Catriona M McNeil

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Michael B Atkins

9

object named as

Michael B Atkins

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Nageatte Ibrahim

23

object named as

Nageatte Ibrahim

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Victoria Atkinson

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Michael B Jameson

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Bernie M Fitzharris

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Andrew G Hill

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Wen-Jen Hwu

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Babak Tamjid

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Archana Srivastava

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Anna J Lomax

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Mohammed Islam

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Xinxin Shu

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Scot Ebbinghaus

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 July 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1202-1210

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor Immunotherapy Directed at PD-1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930428-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30428-X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28729151%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38669331&oldid=2074843564"